| Aug 13 |
Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates
|
| Aug 13 |
Ovid Therapeutics GAAP EPS of $0.12, revenue of $0.17M
|
| Aug 13 |
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
|
| Aug 13 |
Lilly opens R&D hub; Ovid and Lexicon lay off staff
|
| Aug 8 |
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
|
| Jul 30 |
Ovid Therapeutics to Present at Upcoming August Investor Conferences
|
| Jul 23 |
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
|
| Jul 15 |
Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds?
|
| Jul 10 |
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
|
